Tong Joo (TJ) Gan was named division head of Anesthesiology, Critical Care, and Pain Medicine at The University of Texas MD Anderson Cancer Center.
The Ralph Lauren Corporate Foundation will provide $25 million in grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States.
The Lymphoma Research Foundation awarded 29 grants, totaling more than $5.7 million, to support lymphoma research. The 2022 LRF grantee class represents 17 academic and medical institutions across North America.
The American College of Radiology Radiology Leadership Institute announced the recipients of its annual leadership awards at the 2022 ACR meeting. Individuals will be honored at the RLI Summit in September.
Eighty-seven organizations representing patients with chronic and acute health conditions sent a letter to Congress urging them to improve the diversity of enrollment in clinical trials as part of this year’s Prescription Drug User Fee Act reauthorization.
The Society for Immunotherapy of Cancer opened calls for nominations for the Steven A. Rosenberg Scholars Award May 1. This award provides $150,000 in funding to advance the research of an early career scientist in the field of immunology and cancer immunotherapy.
The Association of Community Cancer Centers is establishing two efforts targeted at improving cancer screening, care, and mortality rates for the Appalachian region of the U.S.
Researchers at The University of Texas MD Anderson Cancer Center identified a strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6.
Effective anti-vaping advertisements geared to teens have the greatest impact when they emphasize the adverse consequences and harms of vaping e-cigarettes, use negative imagery, and avoid memes, hashtags and other “teen-centric” communication styles, according to a study by researchers at UNC Lineberger Comprehensive Cancer Center.
The phase III SKYSCRAPER-01 did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
